Top

Published in:

01-06-2008 | Case Report

Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis

Authors: Misuzu Yamashita, Masamitsu Natsumeda, Koji Takasugi, Akiko Ueno, Kayo Ezawa, Kazuhiko Ezawa

Published in: Modern Rheumatology | Issue 3/2008

Abstract

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive joint destruction that requires aggressive treatment using appropriate disease-modifying antirheumatic drugs (DMARDs). RA patients with renal failure, however, are intolerant to most DMARDs due to the potential toxicity. In Japan, tacrolimus was approved for the treatment of RA in 2005. Based on its pharmacokinetics, tacrolimus may be administered to the patients undergoing hemodialysis. We report two cases of RA patients on hemodialysis treated effectively and safely with tacrolimus.

Basile C, Basile C, Semeraro A. Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transplant. 2002;17:530–31.PubMedCrossRef

Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002;36:75–7.PubMedCrossRef

Iwamoto M, Homma S, Asano Y, Minota S. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol. 2005;34:410–1.PubMedCrossRef

Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005;57:1407–13.PubMedCrossRef

Tanaka Y, Suzuki K, Saito K. Efficacy of tacrolimus for joint destruction in rheumatoid arthritis. Clin Calcium. 2007;17:593–9.PubMed

Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc.1990;22:52–6.PubMed

Venkataramanan R, Jain A, Warty VW, Abu-Elmagd K, Furakawa H, Imventarza O et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc. 1991;23:931–3.PubMed

Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol. 1994;47:727–35.PubMedCrossRef

Möller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633–6.PubMed

10.

Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46:2020–8.PubMedCrossRef

11.

Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004;43:992–9.CrossRef

12.

Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57:110–3.PubMedCrossRef

13.

Wall SM, Johansen MJ, Molony DA, DuBose TD, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28:846–54.PubMedCrossRef

14.

Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29:636–7.PubMed

15.

Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006;45:357–9.CrossRef

Title: Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis
Authors: Misuzu Yamashita
Masamitsu Natsumeda
Koji Takasugi
Akiko Ueno
Kayo Ezawa
Kazuhiko Ezawa
Publication date: 01-06-2008
Publisher: Springer Japan
Published in: Modern Rheumatology / Issue 3/2008
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-008-0044-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Use of etanercept in a patient with rheumatoid arthritis on hemodialysis

Control of chondrogenesis by the transcription factor Sox9

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

Atherothrombotic brain infarction in a patient with pachydermoperiostosis

Reversible posterior leukoencephalopathy syndrome: a possible manifestation of Wegener’s granulomatosis-mediated endothelial injury

Osteoclast cell fusion: mechanisms and molecules

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page